Clinical Trial Update: Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of doravirine/tenofovir/lamivudine (MK-1439A) in treatment-naïve HIV-1 patients with transmitted resistance; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• doravirine/tenofovir/lamivudine (MK-1439A) (doravirine/tenofovir/lamivudine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2019-12-26